Boston Scientific Corp is trading 4.3% down at $44.91 as a hawkish Federal Reserve outlook pressures higher-valuation growth names.
- The Federal Reserve held rates steady but signaled no cuts for 2026, triggering a broader market sell-off and risk-off sentiment.
- The stock is underperforming major U.S. indices, which are currently down approximately 1% in today's session.
- No company-specific news, earnings, or FDA decisions have been reported today, suggesting the move is driven by macroeconomic factors.